Second-Line Chemotherapy with Bleomycin, Methotrexate, and Vinorelbine (BMV) for Patients with Squamous Cell Carcinoma of the Head, Neck and Esophagus (SCC-HN&E) Pretreated with a Cisplatin-Containing Regimen: A Phase II Study

REFERENCES

• Khuri FR, Shin DM, Glisson BS, Lippman SM, Ki Hong W. Treatment of patients with recurrent or metastatic squa-mous cell carcinoma of the head and neck: current status and future directions. Semin Oncol 2000; 27 (Suppl. 8): 25-33.
   Google Scholar
• Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890–1900.
   PubMed Web of Science ®Google Scholar
• Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer Principles and Practice of Oncology, 6th Edition. DeVita VT, Hellman S, Rosenberg SA (Eds.). JB Lippincott Company, Philadelphia 2001: 797-860.
   Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treat-ment of cancer: Targeting the epidermal growth factor recep-tor. Clin Cancer Res 2001; 7: 2958–2970.
   PubMed Web of Science ®Google Scholar
• Burtness BA, Li Y, Flood W et al. Phase-III trial com-paring cisplatin (C) + placebo (P) to anti-epidermal growth fac-tor antibody (EGF-R) C-225 in patients (pts) with metastatic/recurrent head and neck cancer. Proc Am Soc Clin Oncol 2002; 21: 226a.
   Google Scholar
• lop A, Cartel G, Isaia A. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluo-rouracil. Ann Oncol 1998; 9: 225–227.
   Google Scholar
• Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
   PubMed Web of Science ®Google Scholar
• Anonymous, World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset publication 48. WORLD Health Organization, Geneva, 1979.
   Google Scholar
• Numico G, Merlano M. Second-line treatment with Docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol 2002; 13: 331–333.
   PubMed Web of Science ®Google Scholar
• Testolin A, Recher F, Pozza F et al. Vinorelbine (VNB) in pretreated advanced head and neck squamous cell carinoma (AH&NSCC): A phase II study. Proc Am Soc Clin Oncol 1994; 13: 289.
   Google Scholar
• Saxman S, Mann B, Canfield V et al. A phase-II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 1998; 21: 398–400.
   PubMed Web of Science ®Google Scholar
• Huber MH, Lippman SM, Benner SE et al. A phase II study of ifosfamide in recurrent squamous cell carcinoma of head and neck. Am J Clin Oncol 1996; 19: 379–382.
   Google Scholar
• Baroncelli G, La Monica MM. Epirubicin, methotrexate and bleomycin (EMB) in the treatment of recurrent epidermoid carcinoma of the head and neck. Tumori 1992; 78: 330–332.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Shank D, Neuberg D et al. Final report of a phase-II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Oncology Cooperative Group trial (PA390). Cancer 1998; 82: 2270–2274.
   Google Scholar
• Smith RE, Thornton DE, Allen J. A phase-II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995; 22 (Suppl. 6): 41-46.
   Google Scholar
• Schoffski P, Weihkopf T, Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. Anticancer Res 1998; 18: 4751–4756.
   PubMed Web of Science ®Google Scholar
• Airoldi M, Marchionatti S, Pedani F et al. Docetaxel (TXT) + Vinorelbine (VNB) in recurrent (R) heavily pre-treated head and neck cancer (HNC) patients (pts). Proc Am Soc Clin Oncol 1999; 18: 402a.
   Google Scholar
• Catimel G, Vermorken JB, Clavel M et al. A phase-II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trial Group. Ann Oncol 1994; 5: 543–547.
   Google Scholar
• Senzer NN, Soulieres D, Siu L et al. Phase II evalua-tion of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001; 20: 2a.
   Google Scholar
• Cohen EEW, Rosen F, Dekker A et al. Phase-II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2002; 21: 225a.
   Google Scholar
• Kies MS, Arquette MA, Nabell L et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002; 21: 232a.
   Google Scholar
• Baselga J, Trigo JM, Bourhis J et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule plat-inum-based regimen. Proc Am Soc Clin Oncol 2002; 21: 226a.
   Google Scholar
• Ramsey SD, Moinpour CM, Lovato LC et al. Economic analysis of vinorelbine plus cisplatin versus paclitax-el plus carboplatin for advanced non-small-cell lung cancer. J Nati Cancer Inst 2002; 94: 291–297.
   Google Scholar
• Vokes EE, Rosenberg RK, Jahanzeb M, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol 1995; 13: 637–644.
   PubMed Web of Science ®Google Scholar